PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Hard-to-Treat brain cancer
Disease control OngoingThis early-phase study tests a combination of two drugs (acalabrutinib and durvalumab) for people with primary central nervous system lymphoma, a rare brain cancer. The study includes up to 25 patients whose cancer has returned or who cannot take standard high-dose chemotherapy. …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:41 UTC
-
New drug cocktail shows promise for rare brain cancer
Disease control OngoingThis early-phase trial tests a combination of the targeted drug ibrutinib with chemotherapy (TEDDI-R) in people with primary CNS lymphoma, a rare brain cancer. The goal is to find the safest dose and see if the treatment shrinks tumors. About 68 adults with relapsed or untreated …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New hope for brain lymphoma: targeted antibody enters human trials
Disease control OngoingThis study tests a new drug called GNC-038 in people with central nervous system lymphoma that has come back or not responded to treatment. The drug is a special antibody designed to attack cancer cells in the brain and spinal cord. The main goals are to find a safe dose and see …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:29 UTC
-
Can a milder chemo beat the standard for brain lymphoma?
Disease control OngoingThis study tests whether a less intense chemotherapy regimen works better than the standard treatment for people newly diagnosed with primary CNS lymphoma, a rare brain cancer. About 331 adults aged 18-70 will be randomly assigned to receive either the standard MATRix protocol or…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE3 • Sponsor: Klinikum Stuttgart • Aim: Disease control
Last updated May 22, 2026 13:50 UTC